Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
Marco Contoli,1 Paolo Solidoro,2 Fabiano Di Marco,3,4 Nicola Scichilone,5 Angelo Corsico,6 Fulvio Braido,7 Pierachille Santus4,8 1Research Centre on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; 2Cardiovascular and Thoracic Department, Città dell...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-12-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/effects-of-aclidinium-on-determinants-of-copd-severity-symptoms-and-qu-peer-reviewed-article-COPD |
id |
doaj-81d6fd6899db476baf3dc01246188dc1 |
---|---|
record_format |
Article |
spelling |
doaj-81d6fd6899db476baf3dc01246188dc12020-11-25T01:43:56ZengDove Medical PressInternational Journal of COPD1178-20052016-12-01Volume 113043305030338Effects of aclidinium on determinants of COPD severity: symptoms and quality of lifeContoli MSolidoro PDi Marco FScichilone NCorsico ABraido FSantus PMarco Contoli,1 Paolo Solidoro,2 Fabiano Di Marco,3,4 Nicola Scichilone,5 Angelo Corsico,6 Fulvio Braido,7 Pierachille Santus4,8 1Research Centre on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; 2Cardiovascular and Thoracic Department, Città della Salute, Turin, Italy; 3Department of Health Sciences, University of Milan, Milan, Italy; 4Respiratory Unit, San Paolo Hospital, Milan, Italy; 5Department of Internal Medicine, Section of Pulmonology (DIBIMIS), University of Palermo, Palermo, Italy; 6Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 7Allergy and Respiratory Diseases Clinic, DIMI, University of Genoa, IRCS AOU San Martino-IST, Genoa, Italy; 8Pulmonary Rehabilitation Unit, Fondazione Salvatore Maugeri, Scientific Institute of Milan-IRCCS, Milan, Italy Abstract: The pathophysiology of chronic obstructive pulmonary disease (COPD) includes persistent airflow limitation, altered gas exchange, and enhanced chronic inflammatory response. According to disease severity in individual patients, exacerbations and comorbidities frequently occur. The overall nocturnal and daily symptoms have a strong impact on patient quality of life and clinical outcomes. Bronchodilators, by targeting two important aspects of COPD pathophysiology, ie, bronchoconstriction and lung hyperinflation, are the mainstay of therapy for COPD. Aclidinium bromide in particular is an anticholinergic molecule, approved for maintenance bronchodilator treatment of stable COPD, that combines high antimuscarinic activity with strong kinetic selectivity for the M3 receptor subtype. Moreover, the elevated plasma clearance of aclidinium has been related to low systemic bioavailability and low incidence of anticholinergic adverse events, whereas the reduced residence time at M2 receptors provides good cardiovascular safety. Altogether, these characteristics result in a high safety and tolerability profile. This review aims to reappraise the contribution of symptoms and of the level of quality of life determinants on COPD severity and to evaluate how therapeutic strategies with aclidinium may positively impact on these specific determinants of disease severity. Keywords: COPD, quality of life, daily symptoms, LAMA, aclidiniumhttps://www.dovepress.com/effects-of-aclidinium-on-determinants-of-copd-severity-symptoms-and-qu-peer-reviewed-article-COPDCOPDquality of lifedaily symptomsLAMAaclidinium |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Contoli M Solidoro P Di Marco F Scichilone N Corsico A Braido F Santus P |
spellingShingle |
Contoli M Solidoro P Di Marco F Scichilone N Corsico A Braido F Santus P Effects of aclidinium on determinants of COPD severity: symptoms and quality of life International Journal of COPD COPD quality of life daily symptoms LAMA aclidinium |
author_facet |
Contoli M Solidoro P Di Marco F Scichilone N Corsico A Braido F Santus P |
author_sort |
Contoli M |
title |
Effects of aclidinium on determinants of COPD severity: symptoms and quality of life |
title_short |
Effects of aclidinium on determinants of COPD severity: symptoms and quality of life |
title_full |
Effects of aclidinium on determinants of COPD severity: symptoms and quality of life |
title_fullStr |
Effects of aclidinium on determinants of COPD severity: symptoms and quality of life |
title_full_unstemmed |
Effects of aclidinium on determinants of COPD severity: symptoms and quality of life |
title_sort |
effects of aclidinium on determinants of copd severity: symptoms and quality of life |
publisher |
Dove Medical Press |
series |
International Journal of COPD |
issn |
1178-2005 |
publishDate |
2016-12-01 |
description |
Marco Contoli,1 Paolo Solidoro,2 Fabiano Di Marco,3,4 Nicola Scichilone,5 Angelo Corsico,6 Fulvio Braido,7 Pierachille Santus4,8 1Research Centre on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; 2Cardiovascular and Thoracic Department, Città della Salute, Turin, Italy; 3Department of Health Sciences, University of Milan, Milan, Italy; 4Respiratory Unit, San Paolo Hospital, Milan, Italy; 5Department of Internal Medicine, Section of Pulmonology (DIBIMIS), University of Palermo, Palermo, Italy; 6Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 7Allergy and Respiratory Diseases Clinic, DIMI, University of Genoa, IRCS AOU San Martino-IST, Genoa, Italy; 8Pulmonary Rehabilitation Unit, Fondazione Salvatore Maugeri, Scientific Institute of Milan-IRCCS, Milan, Italy Abstract: The pathophysiology of chronic obstructive pulmonary disease (COPD) includes persistent airflow limitation, altered gas exchange, and enhanced chronic inflammatory response. According to disease severity in individual patients, exacerbations and comorbidities frequently occur. The overall nocturnal and daily symptoms have a strong impact on patient quality of life and clinical outcomes. Bronchodilators, by targeting two important aspects of COPD pathophysiology, ie, bronchoconstriction and lung hyperinflation, are the mainstay of therapy for COPD. Aclidinium bromide in particular is an anticholinergic molecule, approved for maintenance bronchodilator treatment of stable COPD, that combines high antimuscarinic activity with strong kinetic selectivity for the M3 receptor subtype. Moreover, the elevated plasma clearance of aclidinium has been related to low systemic bioavailability and low incidence of anticholinergic adverse events, whereas the reduced residence time at M2 receptors provides good cardiovascular safety. Altogether, these characteristics result in a high safety and tolerability profile. This review aims to reappraise the contribution of symptoms and of the level of quality of life determinants on COPD severity and to evaluate how therapeutic strategies with aclidinium may positively impact on these specific determinants of disease severity. Keywords: COPD, quality of life, daily symptoms, LAMA, aclidinium |
topic |
COPD quality of life daily symptoms LAMA aclidinium |
url |
https://www.dovepress.com/effects-of-aclidinium-on-determinants-of-copd-severity-symptoms-and-qu-peer-reviewed-article-COPD |
work_keys_str_mv |
AT contolim effectsofaclidiniumondeterminantsofcopdseveritysymptomsandqualityoflife AT solidorop effectsofaclidiniumondeterminantsofcopdseveritysymptomsandqualityoflife AT dimarcof effectsofaclidiniumondeterminantsofcopdseveritysymptomsandqualityoflife AT scichilonen effectsofaclidiniumondeterminantsofcopdseveritysymptomsandqualityoflife AT corsicoa effectsofaclidiniumondeterminantsofcopdseveritysymptomsandqualityoflife AT braidof effectsofaclidiniumondeterminantsofcopdseveritysymptomsandqualityoflife AT santusp effectsofaclidiniumondeterminantsofcopdseveritysymptomsandqualityoflife |
_version_ |
1725030703970648064 |